Article and Video CATEGORIES

Cancer Journey

Search By

Doc, Am I Too Old for Chemo?
Author
dr dubey

The average age at which lung cancer is diagnosed in the US is 71. Would it be fair to say that at least half of those who are diagnosed with lung cancer are elderly? How do we define “old”? How does age impact the effect of chemotherapy?

Two decades ago, analysis of “older patients” who received chemotherapy for advanced lung cancer revealed that chemotherapy improved survival in the elderly to the same extent as in patients who were younger. The down side was that older patients experienced more side effects from chemotherapy. It is easy to see how this result could lead to mixed feelings: live longer, but with side effects. In the 1990’s clinical trials directed towards the elderly began. The pivotal trial was called ELVIS (Elderly Lung cancer Vinorelbine Italian Study). This study compared the effect of chemotherapy (vinorelbine) against no chemotherapy in lung cancer patients ≥70 years of age. This direct comparison clearly demonstrated that chemotherapy not only improved survival but most importantly, quality of life.

How was this possible? We all recognize that controlling the cancer will control cancer related symptoms. The challenge with treatment is balancing the side effects of chemotherapy against the benefit gained by controlling lung cancer symptoms. However, vinorelbine (Navelbine) is a well tolerated chemotherapy that made it possible to improve quality of life. Subsequently, more trials in more modern times with more modern chemotherapy have repeatedly shown us that chemotherapy is feasible and worthwhile in the elderly.

Moving to early non-small cell lung cancer, post operative chemotherapy is the standard of care. The JBR10 clinical trial was one of the trials that compared postoperative chemotherapy to no postoperative chemotherapy and showed us that post-operative chemotherapy improves cure rates. This study also helped us understand the interaction of such treatment with age:

JBR.10 chemo by age

(Click to enlarge)

Patients older than the age of 65 years received less chemotherapy overall than the younger cohort, yet they benefited from post operative chemotherapy with increased survival. This study also showed us that chemotherapy did not seem to have a benefit in patients older than the age of 75, though this is a group of patients in whom deaths unrelated to cancer were common, unlike the younger population, so there were "competing risks".

The caveat to clinical trial results is that patients enrolling onto clinical trials are “fit” and extrapolating results of these trials to the “unfit elderly” has obvious flaws. As treating oncologists we recognize that more important that age is one’s “fitness” or performance status: the ability to take care of oneself, participate in physical activity, the amount of time spent resting or the amount of time spent in bed. If you wonder why your oncologist asks you how many hours in a day you sleep, it is for this reason. There are 2 scales that help us assess peroformance status. One is called the Karnofsky scale, and the other is the Zubrod scale (which is also commonly referred to as the ECOG scale):

Performance Status Scales

Years of cancer care have provided the guidelines that chemotherapy should be administered only when the performance status is good and not poor. It is this functional status scale that is the most important when making treatment decisions with the elderly, eclipsing the importance of chronologic age.

In summary, chemotherapy when carefully tailored to the fit the performance status of elderly patients does provide the benefits of improved survival and quality of life. There doesn't appear to be anything about age as a number that makes a patient "too old for chemo".

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on